Jeffrey H Kordower1,2, Christopher G Goetz1, Yaping Chu1, Glenda M Halliday3, Daniel A Nicholson1, Timothy F Musial1, David J Marmion1, A Jon Stoessl4, Vesna Sossi4, Thomas B Freeman5, C Warren Olanow6. 1. Department of Neurological Sciences, Rush University Medical Center, Chicago, IL. 2. Van Andel Institute, Grand Rapids, MI. 3. Neuroscience Research Australia and Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia. 4. Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada. 5. Department of Neurosurgery and Brain Repair, University of South Florida, Tampa, FL. 6. Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY.
Abstract
OBJECTIVE: The main goal of dopamine cell replacement therapy in Parkinson disease (PD) is to provide clinical benefit mediated by graft survival with nigrostriatal reinnervation. We report a dichotomy between graft structure and clinical function in a patient dying 16 years following fetal nigral grafting. METHODS: A 55-year-old levodopa-responsive woman with PD received bilateral putaminal fetal mesencephalic grafts as part of an NIH-sponsored double-blind sham-controlled trial. The patient never experienced clinical benefit, and her course was complicated by the development of graft-related dyskinesias. Fluorodopa positron emission tomography demonstrated significant increases postgrafting bilaterally. She experienced worsening of parkinsonism with severe dyskinesias, and underwent subthalamic nucleus deep brain stimulation 8 years after grafting. She died 16 years after transplantation. RESULTS: Postmortem analyses confirmed the diagnosis of PD and demonstrated >300,000 tyrosine hydroxylase (TH)-positive grafted cells per side with normalized striatal TH-immunoreactive fiber innervation and bidirectional synaptic connectivity. Twenty-seven percent and 17% of grafted neurons were serine 129-phosphorylated α-synuclein positive in the left and right putamen, respectively. INTERPRETATION: These findings represent the largest number of surviving dopamine neurons and the densest and most widespread graft-mediated striatal dopamine reinnervation following a transplant procedure reported to date. Despite this, clinical recovery was not observed. Furthermore, the grafts were associated with a form of dyskinesias that resembled diphasic dyskinesia and persisted in the off-medication state. We hypothesize that the grafted cells produced a low level of dopamine sufficient to cause a levodopa-independent continuous form of diphasic dyskinesias, but insufficient to provide an antiparkinsonian benefit. ANN NEUROL 2017;81:46-57.
OBJECTIVE: The main goal of dopamine cell replacement therapy in Parkinson disease (PD) is to provide clinical benefit mediated by graft survival with nigrostriatal reinnervation. We report a dichotomy between graft structure and clinical function in a patient dying 16 years following fetal nigral grafting. METHODS: A 55-year-old levodopa-responsive woman with PD received bilateral putaminal fetal mesencephalic grafts as part of an NIH-sponsored double-blind sham-controlled trial. The patient never experienced clinical benefit, and her course was complicated by the development of graft-related dyskinesias. Fluorodopa positron emission tomography demonstrated significant increases postgrafting bilaterally. She experienced worsening of parkinsonism with severe dyskinesias, and underwent subthalamic nucleus deep brain stimulation 8 years after grafting. She died 16 years after transplantation. RESULTS: Postmortem analyses confirmed the diagnosis of PD and demonstrated >300,000 tyrosine hydroxylase (TH)-positive grafted cells per side with normalized striatal TH-immunoreactive fiber innervation and bidirectional synaptic connectivity. Twenty-seven percent and 17% of grafted neurons were serine 129-phosphorylated α-synuclein positive in the left and right putamen, respectively. INTERPRETATION: These findings represent the largest number of surviving dopamine neurons and the densest and most widespread graft-mediated striatal dopamine reinnervation following a transplant procedure reported to date. Despite this, clinical recovery was not observed. Furthermore, the grafts were associated with a form of dyskinesias that resembled diphasic dyskinesia and persisted in the off-medication state. We hypothesize that the grafted cells produced a low level of dopamine sufficient to cause a levodopa-independent continuous form of diphasic dyskinesias, but insufficient to provide an antiparkinsonian benefit. ANN NEUROL 2017;81:46-57.
Authors: J H Kordower; J M Rosenstein; T J Collier; M A Burke; E Y Chen; J M Li; L Martel; A E Levey; E J Mufson; T B Freeman; C W Olanow Journal: J Comp Neurol Date: 1996-06-24 Impact factor: 3.215
Authors: C Warren Olanow; Jean-Michel Gracies; Christopher G Goetz; A Jon Stoessl; Thomas Freeman; Jeffrey H Kordower; James Godbold; Jose A Obeso Journal: Mov Disord Date: 2009-02-15 Impact factor: 10.338
Authors: Michael F Salvatore; Jennifer Terrebonne; Mark A Cantu; Tamara R McInnis; Katy Venable; Parker Kelley; Ella A Kasanga; Brian Latimer; Catherine L Owens; Brandon S Pruett; Yongmei Yu; Robert Luedtke; Michael J Forster; Nathalie Sumien; Donald K Ingram Journal: J Gerontol A Biol Sci Med Sci Date: 2017-12-12 Impact factor: 6.053
Authors: Michael F Salvatore; Tamara R McInnis; Mark A Cantu; Deana M Apple; Brandon S Pruett Journal: Mol Neurobiol Date: 2018-07-28 Impact factor: 5.590
Authors: Michael F Salvatore; Ella A Kasanga; D Parker Kelley; Katy E Venable; Tamara R McInnis; Mark A Cantu; Jennifer Terrebonne; Kathryn Lanza; Samantha M Meadows; Ashley Centner; Christopher Bishop; Donald K Ingram Journal: Geroscience Date: 2022-05-30 Impact factor: 7.713
Authors: Yaping Chu; Scott Muller; Adriana Tavares; Olivier Barret; David Alagille; John Seibyl; Gilles Tamagnan; Ken Marek; Kelvin C Luk; John Q Trojanowski; Virginia M Y Lee; Jeffrey H Kordower Journal: Brain Date: 2019-11-01 Impact factor: 13.501
Authors: Fredric P Manfredsson; Kelvin C Luk; Matthew J Benskey; Aysegul Gezer; Joanna Garcia; Nathan C Kuhn; Ivette M Sandoval; Joseph R Patterson; Alana O'Mara; Reid Yonkers; Jeffrey H Kordower Journal: Neurobiol Dis Date: 2018-01-16 Impact factor: 5.996